# US 2025/0084140 A1 · Compositions from gastrointestinal tract mucins, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084140 A1
- Document ID: US20250084140A1
- Status: Published application
- Kind: A1
- Application number: 18/882,689
- Filed: 2024-09-11
- Published: 2025-03-13
- Earliest claimed: 2018-11-19
- Assignees: Gnubiotics Sciences SA
- Applicants: Gnubiotics Sciences SA
- Inventors: Sara Vidal López; Adeyemi Adesokan; Yong Miao
- Web page: https://patentgrep.com/patent/US20250084140A1

## CPC

- C07K 14/4727: {Mucins, e.g. human intestinal mucin}
- A23K 20/147: Polymeric derivatives, e.g. peptides or proteins
- A23K 20/163: Sugars; Polysaccharides
- A23L 33/18: Peptides; Protein hydrolysates
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/1735: {Mucins, e.g. human intestinal mucin}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are compositions comprising glycopeptides obtained from gastrointestinal mucins that have superior microbiota affects, and methods of manufacture and use thereof. Such compositions are advantageous for pharmaceutical, food stuff and pet food applications.

## Claims

### Claim 1

A method of treating, preventing, or reducing the severity of a pathogenic microorganism infection of the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
b) the oligosaccharide content of the composition is >2% (w/w);
c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
d) the free amino acid content of the composition is <45% (w/w);
e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
i. Hex1HexNAc1
ii. HexNAc2
iii. NeuAc1HexNAc1
iv. NeuGc1HexNAc1
v. Hex1HexNAc1Fuc1
vi. Hex1HexNAc2
vii. Hex1HexNAc2Sul1
viii. NeuAc1Hex1HexNAc1
ix. NeuGc1Hex1HexNAc1
x. NeuAc1HexNAc2
xi. NeuGc1HexNAc2
xii. Hex1HexNAc2Fuc1
xiii. Hex1HexNAc2Fuc1Sul1
xiv. NeuAc1Hex1HexNAc1Fuc1
xv. Hex1HexNAc3Sul1
xvi. Hex2HexNAc2Fuc1
xvii. Hex1HexNAc3Fuc1Sul1
xviii. Hex2HexNAc2Fuc2Sul1, and
g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition comprises glycopeptide-bound oligosaccharides having at least 7 of the structures shown in a) to bb):
a) Galβ1-3GalNAc
b) GlcNAcβ1-6GalNAc
c) NeuAcα2-6GalNAc
d) NeuGcα2-6GalNAc
e) Fucα1-2Galβ1-3GalNAc
f) Gal+GlcNAcβ1-6GalNAc
g) Galβ1-3(GlcNAcβ1-6)GalNAc
h) Galβ1-3GlcNAcβ1-6GalNAc
i) Galβ1-3(GlcNAcβ1-6)GalNAc
j) Galβ1-3(6SGlcNAcβ1-6)GalNAc
k) Galβ1-3(NeuAcα2-6)GalNAc
l) NeuAcαα2-3Galβ1-3GalNAc
m) Galβ1-3(NeuGcα2-6)GalNAc
n) NeuGcα2-3Galβ1-3GalNAc
o) GlcNAc-(NeuAcα2-6)GalNAc
p) GalNAc-(NeuAcα2-6)GalNAc
q) HexNAc-(NeuGcα2-6)GalNAc
r) Fucα1-2(GalNAcα1-3)Galβ1-3GalNAc
s) Fucα1-2Galβ1-4GlcNAcβ1-6GalNAc
t) Fucα1-2Galβ1-3(GlcNAcβ1-6)GalNAc
u) Fucα1-2Galβ1-3(6S-GlcNAcβ1-6)GalNAc
v) Fucα1-2Galβ1-3(NeuAcβ2-6)GalNAc
w) GlcNAcβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAc
x) Galβ1-4GlcNAcβ1-3[(6S)GlcNAcβ1-6]GalNAc
y) Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAc
z) Fucα1-2Galβ1-4(6S)GlcNAcβ1-6[GlcNAcβ1-3]GalNAc
aa) GlcNAcβ1-3[Fucα1-2Galβ1-3(6S-)GlcNAcβ1-6]GalNAc
bb) Fucα1-2Galβ1-3[Fucα1-2Galβ1-4(6S)GlcNAcβ1-6]GalNAc.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the composition comprises glycopeptide-bound oligosaccharides having each of the structures shown in a) to bb).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the composition comprises ten sialylated glycopeptide-bound oligosaccharides.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the sialylated glycopeptide-bound oligosaccharides are selected from the following cc) through ll):
cc) NeuAcα2-6GalNAc
dd) NeuGcα2-6GalNAc
ee) Galβ1-3(NeuAcα2-6)GalNAc
ff) NeuAcαα2-3Galβ1-3GalNAc
gg) Galβ1-3(NeuGcα2-6)GalNAc
hh) NeuGcα2-3Galβ1-3GalNAc
ii) GlcNAc-(NeuAcα2-6)GalNAc
jj) GalNAc-(NeuAcα2-6)GalNAc
kk) HexNAc-(NeuGcα2-6)GalNAc; and
ll) Fucα1-2Galβ1-3(NeuAcβ2-6)GalNAc.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the oligosaccharide content of the composition is >5% (w/w).

### Claim 7 (depends on 1)

The c method according to claim 1, wherein the free amino acid content of the composition is between 33% and 43% (w/w).

### Claim 8 (depends on 1)

The method according to claim 1, having less than 0.1% (w/w) free glycans.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition is capable of inhibiting glycan mediated binding of one or more pathogenic micro-organisms to mucosal cells when orally administered to a subject.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the composition, when orally administered to a subject, is capable of increasing the growth or level of one or more commensal bacteria in the gut of the subject.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the gastrointestinal tract mucins are porcine gastrointestinal tract mucins.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the pathogenic microorganism is selected from Escherichia coli, Helicobacter pylori, Streptococcus spp., Toxoplasma gondii, Plasmodium falciparum, influenza virus, rotavirus, and respirovirus.

### Claim 13

A method of increasing the growth of commensal bacteria in the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
b) the oligosaccharide content of the composition is >2% (w/w);
c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
d) the free amino acid content of the composition is <45% (w/w);
e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
i. Hex1HexNAc1
ii. HexNAc2
iii. NeuAc1HexNAc1
iv. NeuGc1HexNAc1
v. Hex1HexNAc1Fuc1
vi. Hex1HexNAc2
vii. Hex1HexNAc2Sul1
viii. NeuAc1Hex1HexNAc1
ix. NeuGc1Hex1HexNAc1
x. NeuAc1HexNAc2
xi. NeuGc1HexNAc2
xii. Hex1HexNAc2Fuc1
xiii. Hex1HexNAc2Fuc1Sul1
xiv. NeuAc1Hex1HexNAc1Fuc1
xv. Hex1HexNAc3Sul1
xvi. Hex2HexNAc2Fuc1
xvii. Hex1HexNAc3Fuc1Sul1
xviii. Hex2HexNAc2Fuc2Sul1, and
g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the composition comprises glycopeptide-bound oligosaccharides having at least 7 of the structures shown in a) to bb):
a) Galβ1-3GalNAc
b) GlcNAcβ1-6GalNAc
c) NeuAcα2-6GalNAc
d) NeuGcα2-6GalNAc
e) Fucα1-2Galβ1-3GalNAc
f) Gal+GlcNAcβ1-6GalNAc
g) Galβ1-3(GlcNAcβ1-6)GalNAc
h) Galβ1-3GlcNAcβ1-6GalNAc
i) Galβ1-3(GlcNAcβ1-6)GalNAc
j) Galβ1-3(6SGlcNAcβ1-6)GalNAc
k) Galβ1-3(NeuAcα2-6)GalNAc
ll) NeuAcαα2-3Galβ1-3GalNAc
m) Galβ1-3(NeuGcα2-6)GalNAc
n) NeuGcα2-3Galβ1-3GalNAc
o) GlcNAc-(NeuAcα2-6)GalNAc
p) GalNAc-(NeuAcα2-6)GalNAc
q) HexNAc-(NeuGcα2-6)GalNAc
r) Fucα1-2(GalNAcα1-3)Galβ1-3GalNAc
s) Fucα1-2Galβ1-4GlcNAcβ1-6GalNAc
t) Fucα1-2Galβ1-3(GlcNAcβ1-6)GalNAc
u) Fucα1-2Galβ1-3(6S-GlcNAcβ1-6)GalNAc
v) Fucα1-2Galβ1-3(NeuAcβ2-6)GalNAc
w) GlcNAcβ1-3[Galβ1-4(6S)GlcNAcβ1-6]GalNAc
x) Galβ1-4GlcNAcβ1-3[(6S)GlcNAcβ1-6]GalNAc
y) Galβ1-3(Fucα1-2Galβ1-4GlcNAcβ1-6)GalNAc
z) Fucα1-2Galβ1-4(6S)GlcNAcβ1-6[GlcNAcβ1-3]GalNAc
aa) GlcNAcβ1-3[Fucα1-2Galβ1-3(6S-)GlcNAcβ1-6]GalNAc
bb) Fucα1-2Galβ1-3[Fucα1-2Galβ1-4(6S)GlcNAcβ1-6]GalNAc.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the composition comprises ten sialylated glycopeptide-bound oligosaccharides selected from the following cc) through ll):
cc) NeuAcα2-6GalNAc
dd) NeuGcα2-6GalNAc
ee) Galβ1-3(NeuAcα2-6)GalNAc
ff) NeuAcαα2-3Galβ1-3GalNAc
gg) Galβ1-3(NeuGcα2-6)GalNAc
hh) NeuGcα2-3Galβ1-3GalNAc
ii) GlcNAc-(NeuAcα2-6)GalNAc
jj) GalNAc-(NeuAcα2-6)GalNAc
kk) HexNAc-(NeuGcα2-6)GalNAc; and
ll) Fucα1-2Galβ1-3(NeuAcβ2-6)GalNAc.

### Claim 16 (depends on 13)

The method according to claim 13, having less than 0.1% (w/w) free glycans.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the gastrointestinal tract mucins are porcine gastrointestinal tract mucins.

### Claim 18 (depends on 13)

The method of claim 13, wherein the commensal bacteria comprise Coprococcus comes, Prevotella copri, Megamonas spp., or Bacteroides vulgatus.

### Claim 19

A method of increasing production of short chain fatty acid (SCFA) in the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
b) the oligosaccharide content of the composition is >2% (w/w);
c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
d) the free amino acid content of the composition is <45% (w/w);
e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
i. Hex1HexNAc1
ii. HexNAC2
iii. NeuAc1HexNAc1
iv. NeuGc1HexNAc1
v. Hex1HexNAc1Fuc1
vi. Hex1HexNAc2
vii. Hex1HexNAc2Sul1
viii. NeuAc1Hex1HexNAc1
ix. NeuGc1Hex1HexNAc1
x. NeuAc1HexNAc2
xi. NeuGc1HexNAc2
xii. Hex1HexNAc2Fuc1
xiii. Hex1HexNAc2Fuc1Sul1
xiv. NeuAc1Hex1HexNAc1Fuc1
xv. Hex1HexNAc3Sul1
xvi. Hex2HexNAc2Fuc1
xvii. Hex1HexNAc3Fuc1Sul1
xviii. Hex2HexNAc2Fuc2Sul1, and
g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pH in the gut of the subject is decreased.
